Edward Baetge
Center for Beta Cell Therapy in Diabetes
Emmanuel Edward Baetge, Ph.D., has over 30-year experience in conducting and leading research in the biotechnology and pharmaceutical industries. He currently serves as Venture Partner in the firm NanoDimension, where he is focused on investing in breakthrough nutritional and pharmaceutical therapies for health management. He also advises and invests directly in emerging bio-therapeutic approaches through his company Oranssi Innovations, Sàrl. Dr. Baetge serves as a Director at Caelus Health, a Dutch company developing Microbiome based therapeutics for metabolic health; Director at BioKaizen a Swiss Nutritional Profiling company. He is Adjunct Professor at Ecole Polytechnique Fédérale de Lausanne, Switzerland, and was recently appointed as Guest Professor at Vrije Universiteit Brussel with focus on developing medical translation at the Center for Beta Cell Therapy in Diabetes.
From 2010 to 2017, Dr Baetge served as scientific founder and Director of the Nestlé Institute of Health Sciences in Lausanne, Switzerland. The Institute was created with a CHF 500 million, 10-year commitment by Nestlé to develop scientific expertise and discoveries in the application of nutrition for health maintenance and chronic disease prevention.
Before 2010, Dr Baetge was Chief Scientific Officer at ViaCyte in San Diego, California, leading its human stem cell program creating the foremost diabetes stem cell therapy company. During his tenure, this company raised more than $100 M in grants and investments. Before joining ViaCyte, Dr. Baetge was CSO at Modex Therapeutics in Lausanne, Switzerland. Modex developed the first personalized adult stem cell therapy product for treatment of chronic ulcers leading to its successful Swiss IPO in 2002. Before this, he held senior research and scientific management positions at CytoTherapeutics Inc. and Bristol-Myers Squibb.
Dr. Baetge is a pioneer in the use of regenerative medicine for the treatment of diabetes and has an international reputation in the fields of neuroscience, cell therapy and metabolic diseases. He is inventor on a wide range of issued patents covering cell, gene and device technologies.